These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 8113958

  • 1. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
    Zhou LW, Zhang SP, Qin ZH, Weiss B.
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1015-23. PubMed ID: 8113958
    [Abstract] [Full Text] [Related]

  • 2. Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.
    Zhang SP, Zhou LW, Weiss B.
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1462-70. PubMed ID: 7996459
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA.
    Weiss B, Zhou LW, Zhang SP, Qin ZH.
    Neuroscience; 1993 Aug; 55(3):607-12. PubMed ID: 8413923
    [Abstract] [Full Text] [Related]

  • 4. Intrastriatal administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor mRNA inhibits D2 dopamine receptor-mediated behavior and D2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine.
    Zhou LW, Zhang SP, Weiss B.
    Neurochem Int; 1996 Dec; 29(6):583-95. PubMed ID: 9113126
    [Abstract] [Full Text] [Related]

  • 5. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G, Zhou LW, Morabito M, Zhang SP, Weiss B.
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [Abstract] [Full Text] [Related]

  • 6. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ, Marshall JF.
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [Abstract] [Full Text] [Related]

  • 7. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
    Qin ZH, Zhou LW, Zhang SP, Wang Y, Weiss B.
    Mol Pharmacol; 1995 Oct; 48(4):730-7. PubMed ID: 7476901
    [Abstract] [Full Text] [Related]

  • 8. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
    Pollack AE, Thomas LI.
    Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912
    [Abstract] [Full Text] [Related]

  • 9. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK, Manzino L, Heikkila RE.
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [Abstract] [Full Text] [Related]

  • 10. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
    DeBoer P, Abercrombie ED.
    J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558
    [Abstract] [Full Text] [Related]

  • 11. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS, Joyce JN.
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ, Albers LJ, Le H, Creese I.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [Abstract] [Full Text] [Related]

  • 14. Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine.
    Silvia CP, King GR, Lee TH, Xue ZY, Caron MG, Ellinwood EH.
    Mol Pharmacol; 1994 Jul; 46(1):51-7. PubMed ID: 8058056
    [Abstract] [Full Text] [Related]

  • 15. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
    Boldry RC, Chase TN, Engber TM.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1454-9. PubMed ID: 7903390
    [Abstract] [Full Text] [Related]

  • 16. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Paul ML, Graybiel AM, David JC, Robertson HA.
    J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
    [Abstract] [Full Text] [Related]

  • 17. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
    Chen JF, Aloyo VJ, Weiss B.
    Neuroscience; 1993 Jun; 54(3):669-80. PubMed ID: 8101360
    [Abstract] [Full Text] [Related]

  • 18. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
    Schmidt HD, Pierce RC.
    Neuroscience; 2006 Oct 13; 142(2):451-61. PubMed ID: 16844308
    [Abstract] [Full Text] [Related]

  • 19. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D, Osborn CV.
    Eur J Pharmacol; 2005 Dec 28; 528(1-3):88-94. PubMed ID: 16324697
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.